6 Clinically proven Masimo SET ® Measure-through Motion and Low Perfusion™ pulse oximetry has been shown in more than 10 CCHD screening studies – representing over 300,000 babies – to increase the effectiveness of screening newborns for CCHD. 3-5 Adding screening with pulse oximetry can help clinicians identify CCHD before an infant becomes symptomatic.
2 Traditionally, newborns were observed for evidence of CCHD by physical assessment and monitoring for common symptoms, but studies have shown that physical assessment of newborns alone can be unreliable and may fail to detect some infants with CCHD before discharge. Together, this combined solution enhances the automation of newborn screenings using Dual SET ® Oximetry: two simultaneous measurements of oxygen saturation (SpO 2) at pre- and post-ductal sites by the intuitive Eve application, customized to align with a hospital’s CCHD screening protocol.ĬCHD affects approximately 2.5 to 3 newborns per 1000 live births 1 and requires intervention soon after birth to prevent significant morbidity or mortality later detection in infants also increases the risk of brain damage. The first application of Dual SET ® Oximetry is a significant advancement to Masimo SET ®-guided critical congenital heart disease (CCHD) screening, with the CE marking and European launch of the Masimo SET ® MOC-9 ® module and the addition of the Eve™ CCHD Newborn Screening Application for Root. NEUCHATEL, Switzerland-( BUSINESS WIRE)- Masimo (NASDAQ: MASI) today announced Dual SET ® Pulse Oximetry for Root ®, a highly versatile patient monitoring and connectivity hub.
0 kommentar(er)
